Litigation Details for MYLAN PHARMACEUTICALS INC. v. JANSSEN PHARMACEUTICALS, INC. (E.D. Pa. 2015)
✉ Email this page to a colleague
MYLAN PHARMACEUTICALS INC. v. JANSSEN PHARMACEUTICALS, INC. (E.D. Pa. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-05-29 |
| Court | District Court, E.D. Pennsylvania | Date Terminated | 2015-10-16 |
| Cause | 28:2201 Declaratory Judgement (Insurance) | Assigned To | Mark A. Kearney |
| Jury Demand | None | Referred To | |
| Patents | 8,163,798; 8,629,179 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in MYLAN PHARMACEUTICALS INC. v. JANSSEN PHARMACEUTICALS, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for MYLAN PHARMACEUTICALS INC. v. JANSSEN PHARMACEUTICALS, INC. (E.D. Pa. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-07-30 | 36 | Mylan regarding a separate patent, U.S. Patent No. 8,163,798 (“the ’798 patent). Janssen is wrong and cites…considered on a patent-by-patent basis.4 There is a separate first filer for each patent listed in the…fact that the ’179 patent will expire on the same day as the ’798 patent, the patent at issue in the West…invalidity or non-infringement of U.S. Patent No. 8,629,179 (“the ’179 patent”) was a compulsory counterclaim…one patent is ever compulsory in an infringement action based on a separately issued U.S. patent. Moreover | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
